Technology Matches Patients’ Genetic Testing with Clinical Trials Nationwide
GenomOncology and UH Seidman Cancer Center enter into a partnership to increase clinical trial accrual rates.
Read MorePosted by Melanie Hamilton-Basich | Mar 18, 2021 | Cancer |
GenomOncology and UH Seidman Cancer Center enter into a partnership to increase clinical trial accrual rates.
Read MorePosted by | Nov 22, 2019 | Culture Media |
New kit achieves over 90% correlation rate with biopsied embryos and testing spent culture media.
Read MorePosted by Steve Halasey | Oct 8, 2019 | Breast |
Current testing guidelines miss new gene-cancer associations that have the potential to impact care, study says.
Read MorePosted by Chaunie Brusie | Mar 20, 2019 | Breast, Melanoma |
Study data demonstrate that about half of patients have clinically actionable mutations that are being missed.
Read MorePosted by Steve Halasey | Nov 7, 2018 | Diagnostic Technologies |
In a safety communication issued at the beginning of November 2018, FDA alerted patients and healthcare providers that many claims about the ability of direct-to-consumer pharmacogenetic tests to predict a patient’s response to specific medications have not been reviewed by the agency, and may not be supported by scientific or clinical evidence for most medications.
Read More